ReviewCurrent medicinal chemistry2014
Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.
Review in Current medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 86 citations in OpenAlex.
- Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND).Biomolecules · 2026Review
- New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.Viruses · 2024Review
- Tricaprylin-based drug crystalline suspension for intramuscular long-acting delivery of entecavir with alleviated local inflammation.Bioengineering & translational medicine · 2024Article
- Effects of Antiretroviral Treatment on Central and Peripheral Immune Response in Mice with EcoHIV Infection.Cells · 2024Article
- Delivering CRISPR to the HIV-1 reservoirs.Frontiers in microbiology · 2024Review
- The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors.Viruses · 2023Review
- Strategies to improve the physicochemical properties of peptide-based drugs.Pharmaceutical research · 2023Review
- Review
- A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives.Acta pharmaceutica Sinica. B · 2021Review
- Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021Review
- The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy.Clinical pharmacology and therapeutics · 2021Review
- Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19.Emergent materials · 2021Review
- The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.Viruses · 2020Review
- Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.Theranostics · 2020Article
- Synthesis of a long acting nanoformulated emtricitabine ProTide.Biomaterials · 2019Article
- Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment.Expert opinion on drug delivery · 2019Review
- Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice.Nature communications · 2019Article
- Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment.Expert opinion on drug metabolism & toxicology · 2019Review
- Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress.Molecular neurobiology · 2019Article
- Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.International journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Human immunodeficiency virus (HIV) infection commonly results in a myriad of comorbid conditions secondary to immune deficiency. Infection also affects broad organ system function. Although current antiretroviral therapy (ART) reduces disease morbidity and mortality through effective control of peripheral viral load, restricted infection in HIV reservoirs including gut, lymphoid and central nervous system tissues, is not eliminated. What underlies these events is, in part, poor ART penetrance into each organ across tissue barriers, viral mutation and the longevity of infected cells. We posit that one means to improve these disease outcomes is through nanotechnology. To this end, this review discusses a broad range of cutting-edge nanomedicines and nanomedicine platforms that are or can be used to improve ART delivery. Discussion points include how polymer-drug conjugates, dendrimers, micelles, liposomes, solid lipid nanoparticles and polymeric nanoparticles can be harnessed to best yield cell-based delivery systems. When completely developed, such nanomedicine platforms have the potential to clear reservoirs of viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.